Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
- Conditions
- Unresectable Hepatocellular Carcinoma (HCC)Liver Metastases From Colorectal Cancer (mCRC)
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Sirtex Medical
- Target Recruit Count
- 845
- Registration Number
- NCT05967143
- Locations
- 🇫🇷
Hôpital Beaujon, Clichy, Cedex, France
🇫🇷Hopital Henri Mondor, Créteil, Paris, France
🇫🇷Hospices Civils de Lyon HCL Centre Hospitalier Lyon-Sud, Pierre-Bénite, Rhône, France
SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA
- Conditions
- CarcinomaCarcinoma, HepatocellularLiver Neoplasm
- Interventions
- Drug: 99mTc-Macro Albumin Aggregate
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Sirtex Medical
- Target Recruit Count
- 5
- Registration Number
- NCT05848947
- Locations
- 🇺🇸
Inland Imaging, Spokane, Washington, United States
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
- Conditions
- Unresectable Hepatocellular CarcinomaBCLC Stage A Hepatocellular CarcinomaBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular Carcinoma
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Sirtex Medical
- Target Recruit Count
- 100
- Registration Number
- NCT04736121
- Locations
- 🇺🇸
University of California Los Angeles - Ronald Reagan Medical Center, Los Angeles, California, United States
🇺🇸Providence St. Joseph Hospital, Orange, California, United States
🇺🇸University of California Irvine, Orange, California, United States
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
- Conditions
- Intrahepatic Cholangiocarcinoma
- Interventions
- Drug: Cisplatin-gemcitabine
- First Posted Date
- 2016-06-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Sirtex Medical
- Target Recruit Count
- 89
- Registration Number
- NCT02807181
- Locations
- 🇺🇸
Providence Health Care, Spokane, Washington, United States
🇦🇺Macquarie University Hospital, North Ryde, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Drug: FOLFOX6mDevice: SIR-Spheres microspheres
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- Sirtex Medical
- Target Recruit Count
- 209
- Registration Number
- NCT01721954
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Orlando Health, Orlando, Florida, United States
🇺🇸Memorial Healthcare, Pembroke Pines, Florida, United States
- Prev
- 1
- 2
- Next
News
RenovoRx Reports Strong Q2 2025 Commercial Growth and Positive Phase III Trial Continuation
RenovoRx achieved over $400,000 in second quarter 2025 revenue from commercial sales of its FDA-cleared RenovoCath drug-delivery device, marking strong growth in its first two full quarters of commercialization.
Sirtex Medical's SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for Unresectable Hepatocellular Carcinoma
The FDA approved SIR-Spheres Y-90 resin microspheres for treating unresectable hepatocellular carcinoma, making it the first and only radioembolization therapy in the U.S. approved for both HCC and metastatic colorectal cancer.